Five-Year Incidence of Progression to Ankle Osteoarthritis in Patients with and without Glucagon-like Peptide-1 Receptor Agonist Therapy
{{output}}
BackgroundGlucagon-like peptide-1 receptor agonists (GLP) are widely prescribed for type 2 diabetes mellitus (T2DM) and obesity, with established metabolic and anti-inflammatory benefits. Their musculoskeletal impact, particularly on joint-specific outcomes su... ...
